P 39. Evaluation of cognitive subtypes in Parkinson's disease – Correlations with qEEG power spectra

Dopaminergic medication for Parkinson's disease (PD) modulates neuronal oscillations and functional connectivity across the basal ganglia-thalamic-cortical circuit. However, the non-oscillatory component of the neuronal activity, potentially indicating a state of excitation/inhibition balance, has not yet been investigated and previous studies have shown inconsistent changes of cortico-cortical connectivity as a response to dopaminergic medication. To further elucidate changes of regional non-oscillatory component of the neuronal power spectra, functional connectivity, and to determine which aspects of network organization obtained with graph theory respond to dopaminergic medication, we analyzed a resting-state EEG (Electroencephalogram) dataset including 15 PD patients during OFF and ON medication conditions. We found that the spectral slope, typically used to quantify the broadband non-oscillatory component of power spectra, steepened particularly in the left central region in the ON compared to OFF condition. In addition, using lagged coherence as a functional connectivity measure, we found that the functional connectivity in the beta frequency range between centro-parietal and frontal regions was enhanced in the ON compared to the OFF condition. After applying graph theory analysis, we observed that at the lower level of topology the node degree was increased, particularly in the centro-parietal area. Yet, results showed no significant difference in global topological organization between the two conditions: either in global efficiency or clustering coefficient for measuring global and local integration, respectively. Interestingly, we found a close association between local/global spectral slope and functional network global efficiency in the OFF condition, suggesting a crucial role of local non-oscillatory dynamics in forming the functional global integration which characterizes PD. These results provide further evidence and a more complete picture for the engagement of multiple cortical regions at various levels in response to dopaminergic medication in PD.

Download Full-text

GAIT SPECTRAL ANALYSIS: AN EASY FAST QUANTITATIVE METHOD FOR DIAGNOSING PARKINSON'S DISEASE

Journal of Mechanics in Medicine and Biology ◽

10.1142/s0219519411004691 ◽

2012 ◽

Vol 12 (03) ◽

pp. 1250041 ◽

Cited By ~ 10

Author(s):

YASHAR SARBAZ ◽

FARZAD TOWHIDKHAH ◽

SHAHRIAR GHARIBZADEH ◽

AYYOOB JAFARI

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Clinical Data ◽

Power Spectra ◽

Final Diagnosis ◽

Peak Frequency ◽

Main Peak ◽

Significant Difference ◽

Frequency Components

At present, there is no quantitative test to definitely diagnose Parkinson's disease (PD). For this purpose, we computed the power spectra of stride and swing signals of normal persons and patients. The evaluation of power spectra in stride on normal group shows that the main peak of the frequency range is in the range of 0.018 to 0.02 Hz. In contrast, the main peak frequency is different in different PD patients. Our studies on swing signal and its power spectra show that there is a significant difference between the amplitude of frequency components between normal and PD groups. Patients show power spectra amplitude even more than 10 times that of normal patients. The clinical data were obtained from http://www.physionet.org. For measuring time intervals, force sensors were used in the plantar portion of the foot. Power spectra of left stride, right stride, and left swing were computed. Frequency domain of power spectra was divided into 10 parts and then the surface area under each part was calculated. We used artificial neural network for classification of these groups. The clinical data was divided into two parts, training and test sets. An accuracy of 93.75% was obtained during training. The test data was used for validation of the classifier and an accuracy of 92.86% was obtained. The proposed classifier may be used as a tool for helping the clinicians to diagnose PD. Surely the final diagnosis should be obtained by an expert neurologist.

Download Full-text

Effects of repetitive transcranial magnetic stimulation on voice and speech in Parkinson's disease

The Journal of Laryngology & Otology ◽

10.1017/s0022215106002787 ◽

2005 ◽

pp. 1

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Transcranial Magnetic Stimulation ◽

Magnetic Stimulation ◽

Repetitive Transcranial Magnetic Stimulation ◽

Voice And Speech

Download Full-text

Emerging Drugs and Targets for Parkinson's Disease

10.1039/9781849737357 ◽

2013 ◽

Cited By ~ 3

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease

Download Full-text

Evaluation of Efferent Auditory System and Hearing Quality in Parkinson's Disease: Is the Difficulty in Speech Understanding in Complex Listening Conditions Related to Neural Degeneration or Aging?

Journal of Speech Language and Hearing Research ◽

10.1044/2020_jslhr-20-00337 ◽

2020 ◽

pp. 1-9

Author(s):

Nuriye Yıldırım Gökay ◽

Bülent Gündüz ◽

Fatih Söke ◽

Recep Karamert

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Auditory System ◽

Otoacoustic Emissions ◽

Pure Tone ◽

Pure Tone Audiometry ◽

Auditory Pathway ◽

Normal Hearing ◽

System Function ◽

Distortion Product

Purpose The effects of neurological diseases on the auditory system have been a notable issue for investigators because the auditory pathway is closely associated with neural systems. The purposes of this study are to evaluate the efferent auditory system function and hearing quality in Parkinson's disease (PD) and to compare the findings with age-matched individuals without PD to present a perspective on aging. Method The study included 35 individuals with PD (mean age of 48.50 ± 8.00 years) and 35 normal-hearing peers (mean age of 49 ± 10 years). The following tests were administered for all participants: the first section of the Speech, Spatial and Qualities of Hearing Scale; pure-tone audiometry, speech audiometry, tympanometry, and acoustic reflexes; and distortion product otoacoustic emissions (DPOAEs) and contralateral suppression of DPOAEs. SPSS Version 25 was used for statistical analyses, and values of p < .05 were considered statistically significant. Results There were no statistically significant differences in the pure-tone audiometry thresholds and DPOAE responses between the individuals with PD and their normal-hearing peers ( p = .732). However, statistically significant differences were found between the groups in suppression levels of DPOAEs and hearing quality ( p < .05). In addition, a statistically significant and positive correlation was found between the amount of suppression at some frequencies and the Speech, Spatial and Qualities of Hearing Scale scores. Conclusions This study indicates that medial olivocochlear efferent system function and the hearing quality of individuals with PD were affected adversely due to the results of PD pathophysiology on the hearing system. For optimal intervention and follow-up, tasks related to hearing quality in daily life can also be added to therapies for PD.

Download Full-text